Squarepoint
ENGN icon

Squarepoint’s enGene Therapeutics ENGN Stock Holding History

Squarepoint’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$373K Buy
215,381
+166,482
+340% +$679K ﹤0.01% 3661
2026
Q1 		$333K Buy
+48,899
New +$435K ﹤0.01% 3629

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Squarepoint's ENGN Position: Q2 2026 in Review

Squarepoint increased its enGene Therapeutics (ENGN) stake by 340% in Q2 2026, buying an estimated $679K and bringing the position to 215,381 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #3661.

Squarepoint first reported a position in ENGN in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Squarepoint held 215,381 shares of enGene Therapeutics worth $373K as of Q2 2026.
  • Squarepoint bought 166,482 enGene Therapeutics shares in Q2 2026, an estimated $679K.
  • enGene Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3661 holding.
  • Squarepoint first reported a position in enGene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.